I’ve spent 11 years in pharma commercial operations and managed markets. If I hear the word "synergy" one more time, I’m retiring early. In this industry, we spend millions on congresses and advisory boards, yet we treat "networking" like a nebulous, unquantifiable KPI. It’s not. It’s a transaction of time for information.
When you are looking for market access medical affairs opportunities, stop looking for "great networking." Start asking yourself: Who is in the room, and what decision are they empowered to make? If you are looking to move the needle on formulary, you don’t need to shake hands with a thousand people; you need to have a focused conversation with the one person who controls the P&T committee agenda.
The Prescriber Trap vs. Payer Engagement
Early in my career, I made the mistake of dragging market access teams to prescriber-heavy congresses. It’s a waste of budget. Your managed care professionals are not trying to convince a general practitioner to write a prescription; they are trying to convince a health system executive that the net price of your asset justifies the clinical outcomes in their specific patient population.
If your strategy involves selling "clinical utility" to a group that is worried about "budget impact," you’ve already lost. Payer engagement events require a shift in language. You aren’t discussing side-effect profiles; you are discussing HTA (Health Technology Assessment) pressure, utilization management, and value-based contract frameworks. If your team isn't prepared to talk about gross-to-net, they shouldn't be at the table.
The Big Three: Where the Real Work Happens
I keep a running spreadsheet of every conference I attend. I track the name, the role of the person I met, and whether that conversation led why attend rare disease access summits to a follow-up action. Based on years of data, these are the venues where you actually find the people who drive market access.
1. AMCP (Academy of Managed Care Pharmacy)
This is the gold standard for payer engagement events. At AMCP, you are dealing with the people who live in the trenches of managed care. You will meet formulary directors, pharmacy benefit managers (PBMs), and medical directors. This isn't where you find the flash; this is where you find the people who will actually look at your dossier and ask why your evidence generation doesn't match their claims data.
2. The Health Management Academy (THMA)
If you want to move beyond the pharmacy benefit and talk to health system executives, this is where you go. THMA is less about the "formulary" and more about the "ecosystem." These stakeholders are looking at integrated care models. If you are launching a complex specialty therapy, these are the people who determine if your drug ever gets a spot in their infusion centers or clinical pathways.
3. Association of Cancer Care Centers (ACCC)
Oncology market access is its own beast. ACCC brings together the multidisciplinary teams—the clinical leads, the administrators, and the oncology program managers. They aren't just looking at the price; they are looking at the execution of care. They care about affordability, patient access programs, Click for more info and whether your drug is going to create a revenue headache or a clinical win.
Comparison of Key Payer Venues
Event Primary Audience Best For AMCP Managed Care Pharmacies, PBMs Formulary positioning & utilization management THMA Health System C-Suite, Executives Strategic partnerships & site-of-care decisions ACCC Oncology Program Managers, Clinical Leads Pathway adoption & infusion center operationsThe Digital Reality: Evidence and UI
We often ignore the digital footprint we leave behind. When I’m vetting a partner or looking for research, I pay attention to the "site-level" maturity of their digital evidence generation tools. It sounds petty, but if I’m on a portal and I’m clicking through a janky Cookie Law Info plugin UI element that doesn’t load or asks for consent six times, I immediately lose confidence in their backend infrastructure.
Why does this matter? Because market access is about trust in data. If your digital tools for reimbursement, economic modeling, or real-world evidence (RWE) generation look like they were built in 2005, the payer will assume your data quality is equally outdated. Payers are data scientists; show them that your digital maturity matches your clinical claims.
Addressing HTA Pressure and Pricing
The conversation is shifting. We aren't just talking about list price anymore. We are talking about long-term value. When you meet these stakeholders at the conferences mentioned above, bring your economic models. If you don't have a clear answer on how your pricing strategy handles HTA pressure, you are just background noise.
Your team needs to be able to answer these three questions for every payer stakeholder they meet:
How does this asset reduce the total cost of care for this patient population? What evidence do we have that is specific to your member demographics? If we enter into a value-based agreement, what are the specific clinical milestones you are willing to measure?
The "Monday Test": What do you do differently?
My biggest annoyance with conference planning is the lack of follow-up. Most teams return from a congress, dump their business cards on a desk, and call it a week. That is a failure of leadership.
Every time I finish a conference, I ask: "What will I do differently on Monday morning?"
- Did I meet someone who pointed out a gap in our value proposition? Update the slide deck. Did I hear a recurring theme about a specific barrier to formulary entry? Flag that for the next advisory board. Did I meet a stakeholder who specifically requested a different format for our economic data? Ensure our digital tools team addresses that UI/UX issue immediately.
Stop focusing on "networking." Start focusing on the market access medical affairs pipeline. If you aren't leaving the conference with at least three specific, actionable changes to your strategy, you didn't go to a conference—you went on a vacation. Be blunt, be prepared, and for the love of everything, don't use the word "streamline." Just get the work done.